Zosano Pharma Corporation

CompanyUnited States

Zosano Pharma Corporation develops 2 assets, the furthest approved (teriparatide in fractures). Mostly peptide acting on PTH1R; based in the United States.

Assets
2
Furthest
Approved
Trials
2
Signals
0

Pipeline

2

  • teriparatide

    Recombinant parathyroid hormone receptor agonist promoting bone formation

    ApprovedPeptidePTH1Rfractureship fracture

  • parathyroid hormone

    PTH receptor agonist delivered transdermally to stimulate bone formation

    Phase 3PeptidePTH1Rosteoporosispostmenopausal women with primary osteoporosis

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials2
  • Similar companies6

Updated 7 Oct 2026 · 43 sources

Intelligence